Bio Roundup: Opioids in Court, IPO Parade, Brain Cancer Bet & More

Posted by |2019-06-03T03:30:09-07:00May 31st, 2019|

[Corrected 5/31/19, 8:48 am ET. See below.] Pharmaceutical companies that make or market opioids have found themselves in legal hot water, and much of the heat is coming from Oklahoma. This week, a trial began litigating Johnson & Johnson’s responsibility for opioid addiction in the Sooner State. Johnson & Johnson (NYSE: JNJ) entered the Norman, […]

The Winners of the 2019 Xconomy Awards San Diego Are…

Posted by |2019-05-29T19:27:32-07:00May 29th, 2019|

The nominees and finalists for the first-ever Xconomy Awards San Diego were an impressive bunch, making it tough for our judges and the editors to pick the winners. There were multiple deserving companies and people in each category. After much discussion and debate, we decided that these winners represent the best of the San Diego […]

The Biotech IPO Queue Grows Longer as Five More Companies File

Posted by |2019-05-28T09:07:41-07:00May 28th, 2019|

The biotech IPO train is rolling onward, with five more companies climbing aboard. The companies, ranging from a late-stage firm looking to finance Phase 3 studies to preclinical companies laying the groundwork for their first drug trials with human subjects, submitted their paperwork to the SEC late Friday—just before the start of Memorial Day weekend. Here’s […]

Stoke Therapeutics Preps IPO to Bring Dravet Syndrome Drug to Clinic

Posted by |2019-05-28T03:30:08-07:00May 24th, 2019|

After Stoke Therapeutics closed $90 million in financing last fall, CEO Ed Kaye signaled his biotech would seek more cash through an IPO soon. The preclinical-stage biotech is now officially on a path to the public markets. In paperwork filed late Thursday with the SEC, Bedford, MA-based Stoke set a preliminary $86 million target for […]

Nektar Forms New Company Inheris to Take Reins on Pain, CNS Drugs

Posted by |2019-05-23T08:43:26-07:00May 23rd, 2019|

If Nektar Therapeutics wins FDA approval this summer for an opioid painkiller it designed to be less addictive than other opioids, another company will usher the new product onto the market. San Francisco-based Nektar (NASDAQ: NKTR) announced Thursday that it formed Inheris Biopharma to take the reins on pain drug NKTR-181, as well as several […]

Cala Health Secures $50M to Launch Anti-Tremor Wrist Device

Posted by |2019-05-22T15:40:37-07:00May 22nd, 2019|

Cala Health announced this week it raised $50 million in a Series C financing that will fund the market introduction of its wristwatch-like device that delivers nerve stimulation as a remedy for tremors of the hands. New investors Novartis, Baird Capital, LifeSci Venture Partners and TriVentures participated in the fundraising round, and were joined by […]

California Life Sciences Fueled by Education, Established Companies

Posted by |2019-05-21T17:47:59-07:00May 21st, 2019|

New medicines, devices, and diagnostics produced by the life sciences community in California are giving clinicians better tools to fight disease and improve quality of life for patients around the world. Emerging technologies, such as stem cell and gene therapies, are beginning to make their mark. According to the California Life Sciences Association (CLSA)’s latest […]

Voyager’s CSO Dinah Sah to Retire, Omar Khwaja Expands Role

Posted by |2019-05-20T15:15:26-07:00May 20th, 2019|

Dinah Sah is retiring from her position as chief scientific officer of Voyager Therapeutics (NASDAQ: VYGR). In her place, the Cambridge, MA-based gene therapy developer said that Chief Medical Officer Omar Khwaja will take on an expanded role as chief medical officer and head of research and development. The changes will happen June 28, but […]

Eiger Bio’s Apelian Gives Notice, Takes CEO Job at Private Biotech

Posted by |2019-05-20T03:30:07-07:00May 17th, 2019|

David Apelian, chief operating officer and executive medical officer at Eiger BioPharmaceuticals (NASDAQ: EIGR) for the past 17 months, is stepping down. The Palo Alto, CA, drug developer said Friday that Apelian accepted an offer to become CEO of an unnamed private biotech company. Apelian, whose last day will be June 14, will remain on […]

ASCO Abstracts: Breast Cancer, Precision Treatments in the Spotlight

Posted by |2019-05-16T10:09:43-07:00May 16th, 2019|

The world’s biggest annual cancer conference is just around the corner. Data presented at the American Society of Clinical Oncology meeting each year can change medical practice and make or break companies whose drugs are under the microscope. That’s what makes even the “abstracts,” or snippets of data revealed a few weeks before the meeting, […]

Whiskey Coffee, Immigration, AI: MassChallenge Austin 2019 Startups

Posted by |2019-05-15T15:48:14-07:00May 15th, 2019|

Austin—MassChallenge has picked the 74 early-stage companies that will eventually compete for a portion of $500,000 in cash as a part of its Austin accelerator program. They’re startups that are developing products in a wide range of sectors, including life sciences, agriculture, and artificial intelligence. A majority of the startups are from Texas, although some […]

Klickstein Leaves NIBR for resTORbio Chief Scientific Officer Role

Posted by |2019-05-14T07:40:45-07:00May 14th, 2019|

Lloyd Klickstein has joined resTORbio (NASDAQ: TORC) as chief scientific officer. Klickstein comes to Boston-based resTORbio from the Novartis Institutes for Biomedical Research (NIBR), where was global head of translational medicine for the new indication discovery unit and the exploratory disease area. Last year, resTORbio reported positive data for lead drug RTB101, which was developed […]
Go to Top